ANI PHARMACEUTICALS, INC Contract Liability (Deferred Revenue)
ANI PHARMACEUTICALS, INC (ANIP) had Contract Liability (Deferred Revenue) of $5.00 million as of 2024-09-30, per its 10-Q filed 2024-11-08.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-11-08
- 2024-09-30: Contract with Customer, Liability, Current $5.00M.
- 2023-12-31: Contract with Customer, Liability, Current $0.00.
- 2022-12-31: Contract with Customer, Liability, Current $0.00.
- 2022-03-31: Contract with Customer, Liability, Current $116.00K.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2024-09-30 | $5.00M 10-Q · filed 2024-11-08 | |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-08 | |
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 | |
| 2022-03-31 | $116.00K 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $100.00K 10-K · filed 2023-03-09 | $87.00K 10-K · filed 2022-03-15 |
| 2021-09-30 | $62.00K 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $62.00K 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $62.00K 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $80.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $112.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $125.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $300.00K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $451.00K 10-K · filed 2021-03-11 | $500.00K 10-Q · filed 2020-05-07 |
| 2019-09-30 | $496.00K 10-Q · filed 2019-11-06 | |
| 2018-12-31 | $711.00K 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |